Source: Annual Congress 2010 - Aspects of severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Cowan, J. Cowan, R. Palmay, A. Williamson, D. R. Taylor (Dunedin, New Zealand). Simvastatin in the treatment of eosinophilic asthma. Eur Respir J 2010; 36: Suppl. 54, 5488

Member's Comments

No comment yet.

Related content which might interest you: Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Source: Eur Respir J 2005; 25: 41-46 Year: 2005 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Eosinophilic airway inflammation in COPD and asthma Source: Annual Congress 2008 - Invasive and noninvasive measurements of lung inflammation Year: 2008 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Novel treatment of eosinophilic bronchitis with allergic fungal sinusitis using mepolizumab Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Eosinophilic inflammation and asthma control Source: Annual Congress 2009 - Inflammation and airways Year: 2009 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 Response to inhaled corticosteroids in patients with non-asthmatic eosinophilic bronchitis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020